Stock AnalizPhibro Animal Health Corp. PAHC
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Phibro Animal Health Corp. (PAHC) is a healthcare company listed in the US with a market value of about $1.5B. In the twelve months to September 30, 2026 it had revenue of $1.5B and net income of $103M, a net margin of 6.7%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is track record (4/5); the weakest is financial health (1/5).
Key numbers: a P/E of 14.3, a price to free cash flow of 67.4, 5-year revenue growth of 13% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 23% below the current price.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.5B | $1.3B | $1.0B | $978M | $942M | $833M | $800M | $828M | $820M | $764M |
| Net income | $103M | $100M | $48M | $2M | $33M | $49M | $54M | $34M | $55M | $65M | $65M |
| Free cash flow | $22M | $10M | $42M | $46M | -$38M | -$5M | $19M | $25M | $17M | $51M | $78M |
| EPS (diluted) | $2.51 | $2.43 | $1.19 | $0.06 | $0.81 | $1.21 | $1.34 | $0.83 | $0.00 | $0.00 | $0.00 |
| Net margin | 6.7% | 6.6% | 3.7% | 0.2% | 3.3% | 5.2% | 6.5% | 4.2% | 6.6% | 7.9% | 8.5% |
| ROIC | — | 12.0% | 7.4% | 7.0% | 6.7% | 9.1% | 10.6% | 9.3% | 14.2% | 17.0% | 19.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $47.00, 31% above the current price; targets range from $37.00 to $55.00; the consensus rating is “Hold”; expected EPS is $3.48 for the fiscal year ending June 30, 2027.
Frequently asked questions
What is Phibro Animal Health’s P/E ratio?
About 14.3, based on the last twelve months of diluted earnings per share (forward P/E about 9.6).
Is Phibro Animal Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 23% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Phibro Animal Health pay a dividend?
Yes. The dividend yield is about 1.36%, and it has paid dividends for 10 years in our data.
Is Phibro Animal Health a good stock to buy?
We do not give buy or sell advice. Phibro Animal Health scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.